Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...